Allopurinol and mortality in hyperuricaemic patients

Rheumatology

Volumn 48, Issue 7, 2009, Pages 804-806

  Luk, Andrew J ^a   Levin, Gregory P ^b   Moore, Elya E ^b   Zhou, Xiao Hua ^a   Kestenbaum, Bryan R ^c   Choi, Hyon K ^d  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b Department of Biostatistics ^*  (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Allopurinol; Gout; Hyperuricaemia; Mortality

Indexed keywords

ALLOPURINOL; URIC ACID;

ADULT; ARTICLE; BODY MASS; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; HAZARD RATIO; HUMAN; HYPERTENSION; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; SENSITIVITY ANALYSIS; URIC ACID BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ALLOPURINOL; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VETERANS;

EID: 67650074894     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep069     Document Type: Article

References (18)

1. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007;116:894-900.
2. Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med 2003;139:761-6.
3. Johnson RJ, Kang DH, Feig D et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003;41: 1183-90.
4. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008;168: 1104-10.
5. Cohen SD, Kimmel PL, Neff R, Agodoa L, Abbott KC. Association of incident gout and mortality in dialysis patients. J Am Soc Nephrol 2008;19:2204-10.
6. Au DH, Udris EM, Fan VS, Curtis JR, McDonell MB, Fihn SD. Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest 2003; 123:1964-9.
7. Maynard C, Chapko MK. Data resources in the Department of Veterans Affairs. Diabetes Care 2004;27(Suppl. 2):B22-6.
8. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-83.
9. Dawson J, Quinn T, Walters M. Uric acid reduction: A new paradigm in the management of cardiovascular risk? Curr Med Chem 2007;14:1879-86.
10. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006;114:2508-16.
11. Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002;106:221-6.
12. Butler R, Morris AD, Belch JJ, Hill A, Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000;35: 746-51.
13. Doehner W, Schoene N, Rauchhaus M et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: Results from 2 placebo-controlled studies. Circulation 2002;105:2619-24.
14. Guthikonda S, Sinkey C, Barenz T, Haynes WG. Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation 2003;107:416-21.
15. Cardillo C, Kilcoyne CM, Cannon RO 3rd, Quyyumi AA, Panza JA. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension 1997;30:57-63.
16. Mercuro G, Vitale C, Cerquetani E et al. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol 2004;94:932-5.
17. Cappola TP, Kass DA, Nelson GS et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 2001;104:2407-11.
18. Gavin AD, Struthers AD. Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart 2005;91:749-53.